Poline Yiu
Medical · New York, NYNPI 1780758045
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AbbVie at 50.5% of the total. Reporting peaked in 2021 at $8,750 and has fallen 99.6% since, to $34 in 2025. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $121.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Ardelyx, Inc.$5K
- Enterra Medical, Inc.$1K
- Gilead$470
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$403
- Nestle Healthcare Nutrition Inc.$99
- plus $402 from 10 others
What the payments were for
- Consulting fees$1,1908%
- Speaking & faculty fees$6,60043%
- Travel & lodging$4,20227%
- Food & beverage$3,38822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $7,774 |
| Ardelyx, Inc. | 7 | $5,073 |
| Enterra Medical, Inc. | 5 | $1,159 |
| Gilead | 18 | $470 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $403 |
| Nestle Healthcare Nutrition Inc. | 5 | $99 |
| Merck | 4 | $89 |
| Redhill Biopharma Inc. | 5 | $84 |
| Pfizer | 2 | $43 |
| Vivus LLC | 2 | $40 |
| Johnson & Johnson | 1 | $34 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$3,050
How this compares
$15,380 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 104 | $72,638 |
| MotegrityPrucalopride Succinate | 11 | $6,005 |
| Omeprazole | 38 | $647 |
| Mirtazapine | 25 | $441 |
| Amitriptyline Hcl | 16 | $306 |
| Pantoprazole Sodium | 15 | $276 |
| Famotidine | 15 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $7,774 | $72,638104 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $21 | $6,00511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in New York
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Maureen ThyneNew York$109K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
- Maria BaldoNew York$40K
- Michael QuerijeroNew York$32K
- Meiting LiangNew York$25K
- Karina SodenNew York$23K
- Noah KiefferNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.